Bandová M, Stachý A, Lucanský A
Nemocnica s poliklinikou, Presov.
Vnitr Lek. 1992 May;38(5):485-9.
An immunoglobulin preparation for i.v. administration, Ivega (Imuna) was administered to 14 patients, 0.4 g/kg on five consecutive days, but also in lower doses. In all investigated patients a rapid onset of the therapeutic effect was observed--regression of haemorrhage and in 11 a concurrent rise of thrombocytes from a mean value of 20.10(9)/l to mean values of 130.10(9)/l with a maximum between the 6th and 14th day after administration. The tolerance of treatment was satisfactory and no side-effects were observed.
一种用于静脉注射的免疫球蛋白制剂Ivega(Imuna)被给予14名患者,连续5天每天0.4 g/kg,也有使用较低剂量的情况。在所有接受调查的患者中,均观察到治疗效果迅速显现——出血症状消退,11名患者的血小板同时从平均20.10(9)/l升至平均130.10(9)/l,最高值出现在给药后第6天至第14天之间。治疗耐受性良好,未观察到副作用。